CompletedNCT03559192
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
This study evaluated the safety and effectiveness of JNJ-67953964 for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-67953964 for people with depression.
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Tucson and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 16, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 181
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Germany, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT03559192
- Official title
Show the full official title
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedTucson, United States · Little Rock, United States · Glendale, United States
46 more locations
- Orange, United States
- Riverside, United States
- San Marcos, United States
- Upland, United States
- Miami, United States
- Miami Springs, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Chicago, United States
- Skokie, United States
- Lake Charles, United States
- Princeton, United States
- Brooklyn, United States
- Staten Island, United States
- Hickory, United States
- Columbus, United States
- Dayton, United States
- Oklahoma City, United States
- Allentown, United States
- Charleston, United States
- Memphis, United States
- West Jordan, United States
- Berlin, Germany
- Schwerin, Germany
- Chisinau, Moldova
- Moscow, Russia
- Orenburg, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Saratov Region, Russia
- Tomsk, Russia
- Yekaterinburg, Russia
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Nove, Ukraine
- Smila, Ukraine
- Barnsley, United Kingdom
- Blackpool, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-67953964 for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-67953964 and Placebo.
Who was this study for?
Listed age limits: 18 years to 64 years.
